Stockreport

Relmada Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF BCG-unresponsive patients) and high overall CRs (95% any-time) with no progression to muscle-invasive disease or grade =3 treatment-related adverse events; the company p [Read more]